The "story" is now easy to understand - after 20 years of toil and shareholder frustration
- ATL1102 is addressing a key pathway in inflammation
- Not just for DMD - but also other disease indications like LGMD, Asthma, MS etc.
- CD49d as a target has been validated
- PUL 2.0 and MRI results from DMD Phase 2A provide exceptional functional data
- The PUL2.0 data, if replicated in EMA Phase 2B would be end point for EMA/FDA early approval
- Lymphocyte and T-cell modulation data presented by ANP show T-cells benefit from ATL1102
- After the 6 month ATL1102 trial - the DMD boys condition reverted back to baseline i.e. T-cell overaction
- Controlling inflammation in DMD is a key player to the boys functional outcomes
- Evidence shows changes at cellular level
- Treats 100% of boys ...compared to Sarepta's Exondys that only treats just 13% Exon skipping boys
- PRV voucher if ANP receives approval is worth ~ $100m
- ...
-...
Sarepta's failed gene therapy results highlight that extra Dystrophin is not the panacea for functional outcomes in DMD - especially after 5 years of age when fibrosis and inflammation sets in.
ATL1102 seems to help with 'matrix deposition' in the muscles - something additional dystrophin cannot help with.
FA wise the "story" could not get better.
I would be amazed if Sarepta didn't get involved with ATL1102 - and take over the US P2B.
Let's see - assuming as Sammy says... the Board don't get trigger happy and sell the farm cheap.
Exciting times.
- Forums
- ASX - By Stock
- PER
- Ann: ANP meeting with US FDA granted for ATL1102 in DMD
Ann: ANP meeting with US FDA granted for ATL1102 in DMD, page-63
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
-0.002(2.44%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.1¢ | 8.1¢ | 8.0¢ | $3.675K | 45.89K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 343 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 343 | 0.080 |
1 | 24999 | 0.079 |
3 | 78158 | 0.078 |
1 | 13844 | 0.077 |
1 | 8000 | 0.076 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 10000 | 1 |
0.083 | 281992 | 3 |
0.084 | 100000 | 1 |
0.085 | 136669 | 3 |
0.086 | 135412 | 3 |
Last trade - 14.33pm 09/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |